Gerard Brady

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4793973/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nature Medicine, 2014, 20, 897-903.	30.7	608
2	Molecular analysis of circulating tumour cells—biology and biomarkers. Nature Reviews Clinical Oncology, 2014, 11, 129-144.	27.6	535
3	Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. Nature Medicine, 2017, 23, 114-119.	30.7	260
4	Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance. Cancer Cell, 2020, 37, 485-495.	16.8	223
5	Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. Cancer Discovery, 2016, 6, 286-299.	9.4	208
6	Vasculogenic mimicry in small cell lung cancer. Nature Communications, 2016, 7, 13322.	12.8	206
7	Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nature Medicine, 2019, 25, 738-743.	30.7	202
8	Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. Nature Medicine, 2019, 25, 1534-1539.	30.7	146
9	Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer. Analyst, The, 2016, 141, 669-678.	3.5	95
10	Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample. Molecular Oncology, 2016, 10, 566-574.	4.6	74
11	Will liquid biopsies improve outcomes for patients with small-cell lung cancer?. Lancet Oncology, The, 2018, 19, e470-e481.	10.7	63
12	Next-Generation Sequencing Analysis and Algorithms for PDX and CDX Models. Molecular Cancer Research, 2017, 15, 1012-1016.	3.4	49
13	Profiling of Circulating Free DNA Using Targeted and Genome-wide Sequencing in Patients with SCLC. Journal of Thoracic Oncology, 2020, 15, 216-230.	1.1	49
14	Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System. Journal of Molecular Diagnostics, 2014, 16, 343-349.	2.8	44
15	Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer. Scientific Reports, 2019, 9, 11610.	3.3	36
16	Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer. Translational Lung Cancer Research, 2017, 6, 454-472.	2.8	27
17	Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer. European Urology Oncology, 2019, 2, 1-11.	5.4	27
18	twoddpcr: an R/Bioconductor package and Shiny app for Droplet Digital PCR analysis. Bioinformatics, 2017, 33, 2743-2745.	4.1	26

GERARD BRADY

#	Article	IF	CITATIONS
19	Development of a circulating miRNA assay to monitor tumor burden: From mouse to man. Molecular Oncology, 2016, 10, 282-291.	4.6	18
20	Molecular analysis of single circulating tumour cells following longâ€ŧerm storage of clinical samples. Molecular Oncology, 2017, 11, 1687-1697.	4.6	12
21	<i>In silico</i> error correction improves cfDNA mutation calling. Bioinformatics, 2019, 35, 2380-2385.	4.1	6
22	Circulating Tumour Cells in Lung Cancer. Recent Results in Cancer Research, 2020, 215, 105-125.	1.8	3